3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
24
Prostatic Neoplasms, Castration-Resistant
4
Prostatic Diseases
3
Neoplasm Metastasis
3
Metastatic Castration-resistant Prostate Cancer
3
Urogenital Neoplasms
2
Triple Negative Breast Neoplasms
2
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
2
Male Urogenital Diseases
2
Genital Diseases, Male
2
Adenocarcinoma
2
Urogenital Diseases
1
Sleep Initiation and Maintenance Disorders
1
Prostate Cancer Metastatic
1
Non-metastatic Castration-resistant Prostate Cancer
1
Neoplasms by Site
1
Neoplasms
1
Metastatic Castration-resistant Prostate Neoplasms
1
Metastatic Castration-resistant Prostate Cancer (mCRPC)
1
High-Risk Localized Prostate Cancer
1
Fatigue
1
Depression
1
Carcinoma, Transitional Cell
1
Carcinoma, Renal Cell
1
Bulbo-Spinal Atrophy, X-Linked
1
Advanced Solid Tumor
1
Interventions
pembrolizumab
21
enfortumab vedotin
13
Gemcitabine
12
Nivolumab
8
Cisplatin
8
Carboplatin
8
Magnetic Resonance Spectroscopy
6
Specimen Handling
5
Docetaxel
5
toripalimab
4
sacituzumab govitecan
4
Paclitaxel
4
Ipilimumab
4
atezolizumab
3
Mitomycin
3
Fluorouracil
3
disitamab vedotin
2
cabozantinib
2
avelumab
2
Radiosurgery
2
Platinum
2
Injections
2
Immunotherapy
2
Fluorodeoxyglucose F18
2
Cyclophosphamide
2
Biopsy
2
zanidatamab
1
tremelimumab
1
tamibarotene
1
talazoparib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Carcinoma, Transitional Cell
×
darolutamide
×
Clear all
NCT06724159
2026-02-17
SOGUG-PRINCIS
Spanish Oncology Genito-Urinary Group
Recruiting
500 enrolled